Bindesina
Itxura
| Bindesina | |
|---|---|
| Formula kimikoa | C43H55N5O7 |
| SMILES kanonikoa | 2D eredua |
| SMILES isomerikoa | CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O |
| MolView | 3D eredua |
| Mota | [[Methyl 13-(10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl)-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate|Methyl 13-(10-carbamoyl-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl)-17-ethyl-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate]] (en) |
| Estereoisomeroa | HHJUWIANJFBDHT-RQOXPLONSA-N |
| Masa molekularra | 753,410149 Da |
| Erabilera | |
| Hartzeko bidea | intravenous infusion and defusion (en) |
| Haurdunaldia | Australian pregnancy category D (en) |
| Rola | tubulin modulators (en) |
| Identifikatzaileak | |
| InChlKey | HHJUWIANJFBDHT-KOTLKJBCSA-N |
| CAS zenbakia | 53643-48-4 |
| ChemSpider | 37302 |
| PubChem | 40839 |
| Reaxys | 7162300 |
| Gmelin | 36373 |
| ChEMBL | CHEMBL219146 |
| EC zenbakia | 258-682-2 |
| ECHA | 100.053.330 |
| MeSH | D014751 |
| RxNorm | 11204 |
| Human Metabolome Database | HMDB0014454 |
| UNII | RSA8KO39WH |
| NDF-RT | N0000171809 |
| KEGG | D01769 |
Bindesina[1] kimioterapian erabiltzen duten Catharanthus roseus landarearen alkaloide antimitotikoa da. Minbizi mota desberdinak tratatzeko erabiltzen dute, leuzemia, linfoma, melanoma, bularreko minbizia eta biriketako minbizia barne.[2]
Erreferentziak
[aldatu | aldatu iturburu kodea]- ↑ Euskalterm: [Farmakoak Hiztegia] [2022]
- ↑ (Ingelesez) Vindesine (Eldisine) : Cancerbackup
Kanpo estekak
[aldatu | aldatu iturburu kodea]
| Artikulu hau medikuntzari buruzko zirriborroa da. Wikipedia lagun dezakezu edukia osatuz. |